Prelude Therapeutics (PRLD)
0.89
-0.05 (-5.19%)
At close: Apr 23, 2025, 3:59 PM
0.88
-0.25%
Pre-market: Apr 24, 2025, 04:03 AM EDT
-5.19% (1D)
| Bid | 0.65 |
| Market Cap | 50.03M |
| Revenue (ttm) | 7M |
| Net Income (ttm) | -127.17M |
| EPS (ttm) | -1.68 |
| PE Ratio (ttm) | -0.53 |
| Forward PE | -0.89 |
| Analyst | Buy |
| Ask | 0.99 |
| Volume | 93,120 |
| Avg. Volume (20D) | 210,231 |
| Open | 0.94 |
| Previous Close | 0.94 |
| Day's Range | 0.86 - 0.94 |
| 52-Week Range | 0.61 - 6.80 |
| Beta | 1.34 |
About PRLD
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selecti...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 25, 2020
Employees 131
Stock Exchange NASDAQ
Ticker Symbol PRLD
Website https://www.preludetx.com
Analyst Forecast
According to 3 analyst ratings, the average rating for PRLD stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 351.37% from the latest price.
Stock Forecasts